Maridebart Cafraglutide
NCT05669599
Amgen · Phase 2 · Completed · Enrollment 592
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Cohort A: Maridebart Cafraglutide | Obesity or overweight | n/r | 52 | ITT | n/r |
| Cohort A: Placebo | Population n/r | n/r | n/r | n/r | n/r |
| Cohort B: Maridebart Cafraglutide | Population n/r | n/r | n/r | n/r | n/r |
| Cohort B: Placebo | Population n/r | n/r | n/r | n/r | n/r |